Table 1 Clinical Characteristics of the Patients
Variable | Total (n = 356) | No BPF (n = 344) | BPF (n = 12) | P |
|---|---|---|---|---|
Age, Mean ± SD | 58.63 ± 8.77 | 58.52 ± 8.67 | 61.75 ± 11.50 | 0.211 |
BMI, Mean ± SD | 22.23 ± 3.03 | 22.28 ± 3.05 | 20.63 ± 1.59 | 0.004 |
Operation duration min, Mean ± SD | 192.19 ± 74.88 | 192.73 ± 75.42 | 176.67 ± 57.66 | 0.466 |
FEV1/FVC, Mean ± SD | 80.88 ± 8.35 | 80.86 ± 8.35 | 81.35 ± 8.94 | 0.843 |
Albumin, Mean ± SD | 45.55 ± 4.30 | 45.77 ± 4.10 | 39.27 ± 5.41 | < .001 |
Sex, n (%) | 1.000 | |||
Female | 18 (5.06) | 18 (5.23) | 0 (0.00) | |
Male | 338 (94.94) | 326 (94.77) | 12 (100.00) | |
Hypertension, n (%) | 0.854 | |||
No | 305 (85.67) | 294 (85.47) | 11 (91.67) | |
Yes | 51 (14.33) | 50 (14.53) | 1 (8.33) | |
CHD, n (%) | 1.000 | |||
No | 340 (95.51) | 328 (95.35) | 12 (100.00) | |
Yes | 16 (4.49) | 16 (4.65) | 0 (0.00) | |
DM, n (%) | 0.118 | |||
No | 338 (94.94) | 328 (95.35) | 10 (83.33) | |
Yes | 18 (5.06) | 16 (4.65) | 2 (16.67) | |
Tumor history, n (%) | 1.000 | |||
No | 347 (97.47) | 335 (97.38) | 12 (100.00) | |
Yes | 9 (2.53) | 9 (2.62) | 0 (0.00) | |
Smoking history, n (%) | 0.985 | |||
No | 103 (28.93) | 99 (28.78) | 4 (33.33) | |
Yes | 253 (71.07) | 245 (71.22) | 8 (66.67) | |
Drinking history, n (%) | 0.516 | |||
No | 252 (70.79) | 242 (70.35) | 10 (83.33) | |
Yes | 104 (29.21) | 102 (29.65) | 2 (16.67) | |
Staging of tumor, n (%) | 0.002 | |||
Benign | 2 (0.56) | 0 (0.00) | 2 (16.67) | |
I | 79 (22.19) | 77 (22.38) | 2 (16.67) | |
II | 121 (33.99) | 117 (34.01) | 4 (33.33) | |
III | 154 (43.26) | 150 (43.60) | 4 (33.33) | |
Neoadjuvant therapy, n (%) | 0.813 | |||
No | 303 (85.11) | 292 (84.88) | 11 (91.67) | |
Yes | 53 (14.89) | 52 (15.12) | 1 (8.33) | |
Neoadjuvant chemotherapy, n (%) | 0.853 | |||
No | 318 (89.33) | 308 (89.53) | 10 (83.33) | |
Yes | 38 (10.67) | 36 (10.47) | 2 (16.67) | |
Neoadjuvant immunotherapy combined with chemotherapy, n (%) | 1.000 | |||
No | 341 | 329 | 11 | |
Yes | 15 | 15 | 1 | |
Surgical procedure, n (%) | 0.061 | |||
LUL | 94 (26.40) | 90 (26.16) | 4 (33.33) | |
LLL | 46 (12.92) | 45 (13.08) | 1 (8.33) | |
LP | 14 (3.93) | 12 (3.49) | 2 (16.67) | |
RUL | 108 (30.34) | 105 (30.52) | 3 (25.00) | |
RML | 24 (6.74) | 24 (6.98) | 0 | |
RLL | 53 (14.89) | 53 (15.41) | 0 | |
RMLL | 17 (4.78) | 15 (4.36) | 2 (16.67) | |
Pathological type, n (%) | 0.156 | |||
Adenocarcinoma | 27 (7.58) | 26 (7.56) | 1 (8.33) | |
Others | 22 (6.18) | 20 (5.81) | 2 (16.67) | |
Squamous cell carcinoma | 307 (86.24) | 298 (86.63) | 9 (75.00) | |
Operation methods, n (%) | 1.000 | |||
VATS | 115 (32.3) | 111 (32.27) | 4 (33.33) | |
Open | 241 (67.7) | 233 (67.73) | 8 (66.67) | |
Anastomotic methods, n (%) | 0.801 | |||
Sleeve lobectomy | 146 (41.01) | 142 (41.28) | 4 (33.33) | |
Bronchial wedge plasty | 210 (58.99) | 202 (58.72) | 8 (66.67) | |
Broncho-vascular plasty Sleeve, n (%) | 1.000 | |||
No | 293 (82.3) | 283 (82.27) | 10 (83.33) | |
Yes | 63 (17.7) | 61 (17.73) | 2 (16.67) | |
Glucocorticoid, n (%) | 0.013 | |||
No | 202 (56.74) | 191 (55.52) | 11 (91.67) | |
Yes | 154 (43.26) | 153 (44.48) | 1 (8.33) |